Press Release

Aug, 23 2022

Boston Scientific Corporation, Abbott, and Terumo Corporation is Expected to Dominate the Asia-Pacific Interventional Cardiology and Peripheral Vascular Devices Market in 2021

Asia-Pacific Interventional Cardiology and Peripheral Vascular Devices Market is expected to grow with the CAGR of 8.4% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-interventional-cardiology-peripheral-vascular-devices-market

Asia-Pacific interventional cardiology and peripheral vascular devices market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Asia-Pacific interventional cardiology and peripheral vascular devices market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In June 2019, Abbott launched a new cardiac catheter called sensor enabled HD grid mapping catheter in India. This device can be inserted in the body to treat heart diseases or while performing interventional surgical procedures which allows physicians to see things differently, capturing and analyzing data in a novel manner to create highly detailed maps of the heart that better differentiate healthy from unhealthy tissue. This improved interventional cardiac product platform of the company.

Boston Scientific Corporation is the dominating player in Asia-Pacific interventional cardiology and peripheral vascular devices market. The other key players existing in the market are Medtronic, BD., Cordis., Abbott., Baxter., AngioDynamics., SMT, Edwards Lifesciences Corporation., Biosensors International Group, Ltd., W. L. Gore & Associates, Inc., Teleflex Incorporated., OrbusNeich Medical Company Limited, Merit Medical Systems., Terumo Medical Corporation, B. Braun Melsungen AG, MicroPort Scientific Corporation, Lepu Medical Technology (Beijing) Co.,Ltd and Koninklijke Philips N.V. among others.

Boston Scientific Corporation

Boston Scientific Corporation is headquartered in Massachusetts, U.S. and was founded in 1979. The company is focused on development, manufacturing and marketing of medical devices by accelerating innovative medical solutions and research to improve patient’s lives. The company has three business segments which are MedSurg, Rhythm and Neuro and Cardiovascular and out of which cardiovascular is focused segment. The company has several product categories electrophysiology products, female pelvic medicine products, gastroenterology products, gastrointestinal surgery products, gynaecology products, interventional cardiology products, interventional radiology products, neurological surgical products, pain management products, pulmonary products, urology products and vascular surgery products and interventional cardiology products is the focused category for the market.

For instance,

  • In May 2014, Boston Scientific Corporation announced in their newsroom that they signed a definite agreement to acquire the Interventional Division of Bayer AG. This acquisition is expected Boston to grow their number of segments in peripheral space including atherectomy and thrombectomy categories. This aided company to strengthen their position in interventional cardiology market.

The company has wide presence across North America, Europe, Asia-Pacific, South America and Middle East and Africa. The company has various subsidiaries including Atritech NV/SA(Belgium), Asthmatx, Inc. (Delaware), Boston Scientific Sdn. Bhd. (Malaysia), Boston Scientific Limited (South Africa), Boston Scientific Ltd.(Thailand) and among others.

Asia-Pacific Interventional Cardiology

Abbott

Abbott was incorporated in the year 1900 and is headquartered in Illinois, U.S. Company is focusing on diagnostics, medical devices, nutrition and branded generic pharmaceuticals. The company has various business segments such as medical devices, diagnostic products, established pharmaceutical products and nutritional products & medical devices is focused segment. The company has two major product categories which are consumers and health care professionals in which healthcare professionals is the focused segment.

  • In June 2019, Abbott launched a new cardiac catheter called sensor enabled HD grid mapping catheter in India. This device can be inserted in the body to treat heart diseases or while performing interventional surgical procedures which allows physicians to see things differently, capturing and analyzing data in a novel manner to create highly detailed maps of the heart that better differentiate healthy from unhealthy tissue. This improved interventional cardiac product platform of the company.

The company has presence across Asia-Pacific, Europe, Middle East and Africa, North America and South America. The company has various subsidiaries including Abbott Administration Inc. (Delaware), Abbott Bioresearch Center, Inc. (Delaware), Abbott Cardiovascular Systems Inc. (California), Abbott Cardiovascular, Inc. (Delaware) and others.

Terumo Corporation

Terumo Corporation was founded in the year 1921 and is headquartered in Tokyo, Japan. The company is an independent, customer-focused provider large portfolio medical products for clinical practice. The company’s business segments are cardiac and vascular company, general hospital company, blood and cell technologies company and cardiac and vascular company is focused segment. The company has many product categories TIS systems, neurovascular division, cardiovascular division, vascular graft division, hospital systems division, alliance division and blood and cell technologies company in which every TIS division and vascular graft division is market focused category.

  • In July 2021, Terumo Corporation announced that the company launched their new product Azur vascular plug which comes in different sizes to treat arterial anatomy ranging from 2.5 mm to 8 mm with short deployment length for increased precision. This product is also complemented with PG Pro peripheral micro catheter which is used for infusion of diagnostic and therapeutic agents. This enhanced company’s interventional cardiology portfolio.

The company has presence across North America, Europe, Asia-Pacific, South America and Middle East and Africa.


Client Testimonials